SFRP2 and ovarian carcinoma: The effectiveness of ICIs in ovarian cancer is limited; however, these findings based on the SFRP2+ fibroblast signature provide new insights for the assessment of immunotherapy and offer guidance on whether OC patients are likely to benefit from such treatments.